Nice article.
It highlights the latest peak sales forecasts for obesity drugs.

Zepbound – $29B by 2033
Orforglipron – $17.2B by 2033

March 25, 2025
Pharma Giants Bet on Next-Generation GLP-1 Treatments to Sustain Growth
https://visiblealpha.com/blog/pharma-giants-bet-on-next-generation-glp-1-treatments-to-sustain-growth/